- Trials with a EudraCT protocol (100)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
100 result(s) found for: Cellular immunity.
Displaying page 1 of 5.
| EudraCT Number: 2015-004406-42 | Sponsor Protocol Number: FCO-TIM-2015-01 | Start Date*: 2016-03-10 |
| Sponsor Name:FIBICO | ||
| Full Title: CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN KIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNI... | ||
| Medical condition: Kidney transplant cytomegalovirus-seropositive | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-004486-41 | Sponsor Protocol Number: 20130401 | Start Date*: 2013-01-29 |
| Sponsor Name:Karolinska University Hospital, Huddinge, Sweden | ||
| Full Title: Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity. | ||
| Medical condition: Patients with IgG-deficiency | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-002928-41 | Sponsor Protocol Number: Immunity_TBE | Start Date*: 2013-01-14 |
| Sponsor Name:Med. Uni. Wien, Klinik für Innere I | ||
| Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study | ||
| Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002088-23 | Sponsor Protocol Number: DemiVac2021 | Start Date*: 2021-05-05 |
| Sponsor Name:Sciensano | ||
| Full Title: Covid-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population (REDU-VAC) | ||
| Medical condition: Healthy persons from age 18 till age 56 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-020450-33 | Sponsor Protocol Number: IX-senesc2.0 | Start Date*: 2010-06-23 | |||||||||||
| Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine | |||||||||||||
| Full Title: Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO® | |||||||||||||
| Medical condition: The aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the Japanese encephalitis vaccine IXIARO in subjects above 65 years of age in comp... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-005800-24 | Sponsor Protocol Number: version1.0 | Start Date*: 2008-10-22 | |||||||||||
| Sponsor Name:Medizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin | |||||||||||||
| Full Title: Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccination | |||||||||||||
| Medical condition: The aim of this project is to investigate the humoral and cellular immune responses of low-responders after TBE vaccination in order to find parameters regarding immunoregulation against TBE. It is... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001901-18 | Sponsor Protocol Number: LGS.MMR.01.2016.2022 | Start Date*: 2017-02-14 | |||||||||||
| Sponsor Name:The Danish National University Hospital "Rigshospitalet" | |||||||||||||
| Full Title: Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting | |||||||||||||
| Medical condition: Infection with measles, mumps or rubella | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003303-18 | Sponsor Protocol Number: rl.01.2013 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Gedeon Richter Polska Sp. z o. o. | ||
| Full Title: Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnose... | ||
| Medical condition: Recurrent airway inflammation in children with impaired cellular immunity. | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: PL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004541-33 | Sponsor Protocol Number: immvzmpr1 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Västra Götalandsregionen | ||
| Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. | ||
| Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ... | ||
| Disease: | ||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-002378-37 | Sponsor Protocol Number: LIS/IMM138 | Start Date*: 2008-12-23 |
| Sponsor Name:National Institute of Health and the Environment (RIVM) | ||
| Full Title: The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination. | ||
| Medical condition: Whooping cough is a respiratory disease caused by Bordetella pertussis. Young infants are mostly at risk, but older children are the main source of infection. Since the incidence of whooping cough... | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-002531-56 | Sponsor Protocol Number: COVICO | Start Date*: 2022-12-28 |
| Sponsor Name:Sciensano | ||
| Full Title: LONGITUDINAL FOLLOW-UP OF SARS-COV-2 (COVID-19) IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026 | ||
| Medical condition: Healthy persons and immunocompromised patients (nursing home residents, dialysis patients and kidney- and lung transplant patients) from age 18 till age 105 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-001709-26 | Sponsor Protocol Number: IMS012012 | Start Date*: 2012-06-28 | |||||||||||
| Sponsor Name:Sevapharma,a.s. | |||||||||||||
| Full Title: Randomized, double-blind, placebo-controlled clinical trial of Immodin immunological efficacy in healthy adult volunteers. | |||||||||||||
| Medical condition: Immunological efficacy, in healthy volunteers | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-004891-33 | Sponsor Protocol Number: T33/2021 | Start Date*: 2022-04-13 |
| Sponsor Name:Turku University Hospital | ||
| Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004419-14 | Sponsor Protocol Number: T125/2020 | Start Date*: 2021-10-18 |
| Sponsor Name:Turku University Hospital | ||
| Full Title: COVID-19 infections in hospital personnel | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-001453-74 | Sponsor Protocol Number: Version01.1. | Start Date*: 2012-05-15 |
| Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine | ||
| Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun® | ||
| Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-005672-34 | Sponsor Protocol Number: FSME_only_1.1 | Start Date*: 2013-03-05 |
| Sponsor Name:Institut für Spezifische Prophylaxe | ||
| Full Title: Application of FSME-Immun® in allergic patients | ||
| Medical condition: Allergic patients have generally an altered immune-responsiveness (Th2 bias), and allergic individuals undergoing de-sensitization display an increased production of immune supressive cytokines. We... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-006754-31 | Sponsor Protocol Number: 80101 | Start Date*: 2022-03-22 |
| Sponsor Name:Leiden University Medical Center | ||
| Full Title: Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers | ||
| Medical condition: Safety and immunogenicity after revaccination with Spikevax in healthy adults who have received Comirnaty as a primary vaccine | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000570-19 | Sponsor Protocol Number: TBE_obesity_1.1 | Start Date*: 2014-07-11 |
| Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine | ||
| Full Title: Applikation of FSME-IMMUN® in obese persons | ||
| Medical condition: Studies have shown that obesity has a direct effect on the immune system and leads to immunosuppression, which leads to a susceptibility to infection. The aim of this study is to clarify if a modif... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-004610-26 | Sponsor Protocol Number: OVG2017/10 | Start Date*: 2018-11-28 | |||||||||||
| Sponsor Name:Clinical Trials and Research Governance (CTRG), University of Oxford | |||||||||||||
| Full Title: Evaluating the Long Term Immunogenicity of adenoviral and MVA vectored Ebola vaccine schedules and response to late boosting with AD26.ZEBOV vaccine: an open-label clinical trial | |||||||||||||
| Medical condition: Ebola Virus Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-003071-20 | Sponsor Protocol Number: C060401 | Start Date*: 2005-09-20 |
| Sponsor Name:FIT Biotech Oyj Plc | ||
| Full Title: Immunogenicity and therapeutic effects of GTU-MultiHIV B clade DNA vaccine. A randomized, controlled, phase II clinical trial in treatment-naive HIV-positive subjects | ||
| Medical condition: Treatment naive HIV infected individuals | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
